Dapagliflozin versus empagliflozin in patients with chronic kidney disease

Article Medicine, General & Internal

Empagliflozin in Patients with Chronic Kidney Disease

William G. Herrington et al.

Summary: Empagliflozin therapy reduces the risk of disease progression or cardiovascular death in patients with chronic kidney disease.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Empagliflozin Improves the MicroRNA Signature of Endothelial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes

Pasquale Mone et al.

Summary: Endothelial dysfunction is a key mechanism in heart failure with preserved ejection fraction (HFpEF), diabetes mellitus (DM), and frailty, but there is a lack of reliable biomarkers to monitor this dysfunction. This study evaluated the expression of circulating microRNAs involved in endothelial function regulation in HFpEF and DM patients treated with empagliflozin, metformin, or insulin. The results showed that specific miRNAs were significantly regulated in HFpEF patients, and two of them (miR-21 and miR-92) were significantly reduced after empagliflozin treatment.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories

Javed Butler et al.

Summary: This study aimed to evaluate the effect of empagliflozin on patients with chronic kidney disease. It was found through a pooled analysis of EMPEROR-Reduced and EMPEROR-Preserved that empagliflozin can reduce the risk of heart failure and heart failure-related death in patients with different risk categories.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes Heart Failure, and Atherosclerotic Cardiovascular Disease Insights From the Department of Veterans Affairs

Aliza Hussain et al.

Summary: This study assessed the utilization of SGLT2 inhibitors in patients with established ASCVD, HF, and T2DM and found low utilization rates and significant facility-level variation. These findings suggest opportunities to optimize the use of SGLT2 inhibitors for preventing future cardiovascular events.

JACC-HEART FAILURE (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Cost-effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes

Bao-Ngoc Nguyen et al.

Summary: This study aimed to examine the cost-effectiveness of adding canagliflozin or dapagliflozin to standard of care (SoC) versus SoC alone in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). The results showed that both canagliflozin + SoC and dapagliflozin + SoC were associated with cost savings and additional quality-adjusted life-years (QALYs) compared with SoC alone. However, dapagliflozin + SoC was not cost-effective compared with canagliflozin + SoC over the lifetime horizon.

DIABETES OBESITY & METABOLISM (2023)

添加到收藏夹

Review Peripheral Vascular Disease

Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart

Gaetano Santulli et al.

Summary: SGLT2 inhibitors have beneficial effects on kidney and heart function, and they can improve physical and cognitive impairment in frail older adults.

HYPERTENSION (2023)

添加到收藏夹

Article Urology & Nephrology

Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials

Hiddo J. L. Heerspink et al.

Summary: The effects of newer kidney protective agents on smaller declines in eGFR have been assessed and found to be comparable to the effects on kidney failure or death due to kidney failure. This suggests that composite endpoints incorporating smaller declines in eGFR can reduce the required number of participants in clinical trials without compromising statistical power.

KIDNEY INTERNATIONAL (2023)

添加到收藏夹

Letter Medicine, General & Internal

Empagliflozin in Patients with Chronic Kidney Disease

Brendon G. Neuen et al.

Summary: The editorial suggests that the benefit of empagliflozin in slowing the progression of chronic kidney disease is less evident among patients who do not receive RAS blockade. This is because this subgroup only accounts for 15% of the overall trial population, resulting in less precise effect estimates and wider confidence intervals.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Urology & Nephrology

Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial

Odette S. Reifsnider et al.

Summary: In patients with type 2 diabetes and established cardiovascular disease, adding empagliflozin to standard of care has shown to be a cost-effective treatment option for diabetic kidney disease, reducing the risk of incident or worsening nephropathy.

AMERICAN JOURNAL OF KIDNEY DISEASES (2022)

添加到收藏夹

Letter Cardiac & Cardiovascular Systems

Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States

Rahul Aggarwal et al.

CIRCULATION-HEART FAILURE (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

The effect of dapagliflozin on ventricular arrhythmias, cardiac arrest, or sudden death in people with heart failure: a tick in another box for sodium-glucose cotransporter 2 inhibitors

Theocharis Koufakis et al.

Summary: Despite the poor prognosis of HFrEF, the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin may help reduce the risk of death caused by ventricular arrhythmias.

EXPERT OPINION ON PHARMACOTHERAPY (2022)

添加到收藏夹

Article Health Care Sciences & Services

Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease

Rebecca L. Tisdale et al.

Summary: This study aimed to evaluate the cost-effectiveness of adding Dapagliflozin to standard care for patients with non-diabetic CKD. The results showed that using Dapagliflozin could prolong life expectancy, reduce CKD progression, and decrease the time on kidney replacement therapy. Additionally, the treatment was deemed cost-effective according to conventional criteria.

JOURNAL OF GENERAL INTERNAL MEDICINE (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction JACC Review Topic of the Week

Jacob A. Udell et al.

Summary: SGLT2 inhibitors show potential in improving cardiovascular outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and chronic heart failure, and may also benefit those with a history of myocardial infarction, when used early.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Cost-Effectiveness of Dapagliflozin for Chronic Kidney Disease in Japan

Satoshi Kodera et al.

Summary: This study assessed the cost-effectiveness of the SGLT2 inhibitor dapagliflozin for CKD stages 3a and 3b. The results showed that dapagliflozin had acceptable cost-effectiveness in CKD stage 3b, but the cost-effectiveness in CKD stage 3a was uncertain.

CIRCULATION JOURNAL (2022)

添加到收藏夹

Article Urology & Nephrology

Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease A Health-Economic Analysis of DAPA-CKD

Phil McEwan et al.

Summary: CKD imposes a significant burden on patients and healthcare providers. The DAPA-CKD trial demonstrated that dapagliflozin, along with standard therapy, can reduce CKD progression and the need for kidney replacement therapy. This study aimed to evaluate the cost-effectiveness of dapagliflozin for CKD treatment from payer perspectives in the UK, Germany, and Spain.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)

添加到收藏夹

Article Urology & Nephrology

Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence

Peter Rossing et al.

KIDNEY INTERNATIONAL (2022)

添加到收藏夹

Article Urology & Nephrology

Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD: A Cross-Sectional Registry Analysis

Min Zhuo et al.

Summary: This study found that the prescription rate of SGLT-2i was low in the CKD population, particularly among patients without diabetes. Factors influencing SGLT-2i prescription included race, age, history of heart failure, and use of cardiovascular medications.

KIDNEY360 (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin's Effects in the Adrenal Gland

Anastasios Lymperopoulos et al.

Summary: SGLT2 inhibitors, such as dapagliflozin, have shown cardiovascular benefits in HF patients, regardless of diabetes co-existence. These drugs have been reported to reduce cardiovascular mortality and hospitalizations, independent of their effects on blood glucose control.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Medicine, General & Internal